Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batiraxcept + Durvalumab in Platinum-Resistant Ovarian Cancer
NCT04019288Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2019
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of batiraxcept in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2019; status: terminated.
02
Drugs
batiraxcept
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04019288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019288.